Bridons research contributions include: Development of Drug Affinity Complex (DAC) technology for albumin binding and peptide half-life extension Identification and characterization of CJC-1295 as a long-lasting GRF analog with sustained growth hormone-releasing properties Pioneering work on maleimido-derivatized GHRH analogs and their bioconjugation to serum albumin Demonstration of 4-fold increase in growth hormone area-under-curve with optimized CJC-1295 formulation versus native GHRH Extensive in vitro and in vivo pharmacological characterization in rat and human models His 2005 publication in Endocrinology titled Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog remains the foundational reference for CJC-1295 research, establishing the peptides mechanism of action and pharmacokinetic profile that enabled subsequent clinical investigation
Cyanocobalamin works and is cheaper, but for ongoing optimization as part of a broader supplement strategy, methylcobalamin is the more direct choice
These findings suggest that low concentrations of curcumin may be suitable for further evaluation as a potential antimicrobial additive in semen extenders
Lancet Child Adolesc Health 3(9):595597 Hansen HH, Barkholt P, Fabricius K, Jelsing J, Terwel D, Pyke C, Knudsen LB, Vrang N (2016) The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy
More on this story Published1 March 2016
